{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:45:55Z","timestamp":1793191555717,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.dmd.2025.100223","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T23:51:44Z","timestamp":1766447504000},"page":"100223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fraction metabolized by cytochrome P450 enzymes: A comprehensive evaluation of the translatability of an in vitro HepatoPac assay"],"prefix":"10.1016","volume":"54","author":[{"given":"Florian","family":"Klammers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanusa","family":"Shanmugalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Remus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schriewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Parrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-3430","authenticated-orcid":false,"given":"Kenichi","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1612","key":"10.1016\/j.dmd.2025.100223_bib1","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2012.0430","article-title":"A world of cytochrome P450s","volume":"368","author":"Nelson","year":"2013","journal-title":"Philos Trans R Soc B Biol Sci"},{"issue":"8","key":"10.1016\/j.dmd.2025.100223_bib2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1124\/dmd.115.069096","article-title":"Evaluation of a new molecular entity as a victim of metabolic drug-drug interactions\u2014an industry perspective","volume":"44","author":"Bohnert","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100223_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cpt.1950","article-title":"Ribociclib drug-drug interactions: clinical evaluations and physiologically-based pharmacokinetic modeling to guide drug labeling","volume":"108","author":"Samant","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2025.100223_bib4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/cpt.1547","article-title":"Prediction of the impact of cytochrome P450 2C9 genotypes on the drug\u2013drug interaction potential of siponimod with physiologically-based pharmacokinetic modeling: a comprehensive approach for drug label recommendations","volume":"106","author":"Huth","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100223_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1029073","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan","volume":"13","author":"Grzegorzewski","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100223_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12272-023-01478-7","article-title":"PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes","volume":"47","author":"Cho","year":"2024","journal-title":"Arch Pharmacal Res"},{"issue":"3","key":"10.1016\/j.dmd.2025.100223_bib7","first-page":"437","article-title":"Clinical exploration and physiologically based modelling of the impact of hepatic impairment on entrectinib pharmacokinetics","volume":"64","author":"Ozbey","year":"2025","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmd.2025.100223_bib8","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/cpt.3386","article-title":"PBPK modeling of entrectinib and its active metabolite to derive dose adjustments in pediatric populations co-administered with CYP3A4 inhibitors","volume":"116","author":"Umehara","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2025.100223_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40262-022-01204-4","article-title":"Can mechanistic static models for drug-drug interactions support regulatory filing for study waivers and label recommendations?","volume":"62","author":"Gomez-Mantilla","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmd.2025.100223_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1208\/s12248-008-9019-6","article-title":"Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates","volume":"10","author":"Harper","year":"2008","journal-title":"AAPS J"},{"issue":"5","key":"10.1016\/j.dmd.2025.100223_bib12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/2472555219831407","article-title":"Application of new cellular and microphysiological systems to drug metabolism optimization and their positioning respective to in silico tools","volume":"24","author":"Docci","year":"2019","journal-title":"SLAS Discov"},{"issue":"4","key":"10.1016\/j.dmd.2025.100223_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100055","article-title":"Prediction of hepatic metabolic clearance in rats and dogs using long-term cocultured hepatocytes","volume":"53","author":"Umehara","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2025.100223_bib14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/dmd.120.000133","article-title":"Application of the Extended Clearance Classification System (ECCS) in drug discovery and development: selection of appropriate in vitro tools and clearance prediction","volume":"48","author":"Umehara","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2025.100223_bib15","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1021\/acs.molpharmaceut.6b00396","article-title":"Use of H\u03bcREL human coculture system for prediction of intrinsic clearance and metabolite formation for slowly metabolized compounds","volume":"13","author":"Hultman","year":"2016","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.dmd.2025.100223_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1208\/s12248-022-00689-y","article-title":"Multi-well array culture of primary human hepatocyte spheroids for clearance extrapolation of slowly metabolized compounds","volume":"24","author":"Preiss","year":"2022","journal-title":"AAPS J"},{"issue":"7","key":"10.1016\/j.dmd.2025.100223_bib17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.120.000340","article-title":"Primary human hepatocyte spheroids as an in vitro tool for investigating drug compounds with low hepatic clearance","volume":"49","author":"Riede","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2025.100223_bib18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/dmd.124.001653","article-title":"Evaluation and optimization of a microcavity plate\u2013based human hepatocyte spheroid model for predicting clearance of slowly metabolized drug candidates","volume":"52","author":"Kukla","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100223_bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.115.067876","article-title":"Novel cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method","volume":"44","author":"Yang","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2025.100223_bib20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1124\/dmd.121.000765","article-title":"Estimation of fraction metabolized by cytochrome P450 enzymes using long-term cocultured human hepatocytes","volume":"50","author":"Klammers","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2025.100223_bib21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nbt1361","article-title":"Microscale culture of human liver cells for drug development","volume":"26","author":"Khetani","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100223_bib22","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1124\/dmd.113.053397","article-title":"Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac","volume":"41","author":"Chan","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2025.100223_bib23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/dmd.120.090951","article-title":"Evaluation of erythromycin as a tool to assess CYP3A contribution of low clearance compounds in a long-term hepatocyte culture","volume":"48","author":"Chan","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2025.100223_bib24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1124\/dmd.121.000601","article-title":"Reaction phenotyping of low-turnover compounds in long-term hepatocyte cultures through persistent selective inhibition of cytochromes P450","volume":"49","author":"Smith","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2025.100223_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100062","article-title":"Evaluation of small interfering RNA\u2013dependent knockdowns of drug-metabolizing enzymes in multiwell array culture of primary human hepatocyte spheroids for estimation of fraction metabolized","volume":"53","author":"Br\u00fccker","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2025.100223_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab"},{"issue":"4","key":"10.1016\/j.dmd.2025.100223_bib27","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3390\/ijms22041662","article-title":"Paroxetine\u2014overview of the molecular mechanisms of action","volume":"22","author":"Kowalska","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.dmd.2025.100223_bib28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/clpt.2014.50","article-title":"Fluoxetine- and norfluoxetine-mediated complex drug\u2013drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4","volume":"95","author":"Sager","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dmd.2025.100223_bib29","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s40262-021-01041-x","article-title":"Influence of CYP2D6 phenotypes on the pharmacokinetics of aripiprazole and dehydro-aripiprazole using a physiologically based pharmacokinetic approach","volume":"60","author":"Kneller","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.dmd.2025.100223_bib30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14737175.2024.2367695","article-title":"An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents","volume":"24","author":"Crump","year":"2024","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"10.1016\/j.dmd.2025.100223_bib31","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/CAD.0000000000001360","article-title":"Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities","volume":"33","author":"Kwok","year":"2022","journal-title":"Anti-Cancer Drugs"},{"issue":"4","key":"10.1016\/j.dmd.2025.100223_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00003088-200645040-00001","article-title":"The clinical pharmacokinetics of darifenacin","volume":"45","author":"Skerjanec","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmd.2025.100223_bib33","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1038\/s41598-025-86450-9","article-title":"Tolterodine is a novel candidate for assessing CYP3A4 activity through metabolic volatiles to predict drug responses","volume":"15","author":"Stock","year":"2025","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.dmd.2025.100223_bib34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00008571-200210000-00010","article-title":"Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers","volume":"12","author":"Kirchheiner","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"4","key":"10.1016\/j.dmd.2025.100223_bib35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00280-011-1793-7","article-title":"The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers","volume":"69","author":"Bello","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100223_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1124\/dmd.114.062620","article-title":"A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement","volume":"43","author":"Kazmi","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2025.100223_bib37","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bcp.2008.07.006","article-title":"The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan","volume":"76","author":"Alonen","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100223_bib38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/bdd.1853","article-title":"Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene","volume":"34","author":"Lehtinen","year":"2013","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2025.100223_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2125.2011.04007.x","article-title":"Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects","volume":"72","author":"Malhotra","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100223_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100051","article-title":"Improved clearance predictions for aldehyde oxidase substrates using a novel triculture human hepatocyte model","volume":"53","author":"Byer-Alcorace","year":"2025","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T02:55:25Z","timestamp":1774666525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625095327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0090955625095327"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100223","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fraction metabolized by cytochrome P450 enzymes: A comprehensive evaluation of the translatability of an in vitro HepatoPac assay","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100223"}}